Form 4: Guardant Health CTO Darya Chudova Reports RSU Vesting

Guardant Health's Chief Technology Officer, Darya Chudova, reported the vesting of various restricted stock units and performance-based restricted stock units on January 1, 2026, alongside shares withheld for tax obligations.

Summary

• Darya Chudova, Chief Technology Officer of Guardant Health, Inc., reported multiple transactions on January 1, 2026, primarily involving the vesting of restricted stock units (RSUs) and performance-based restricted stock units (PBRSUs).
• A total of 22,732 shares of common stock were acquired through the vesting of various RSU and PBRSU awards.
• Specifically, 1,339 RSUs (granted November 7, 2022), 10,714 PBRSUs (granted June 7, 2023), 1,667 RSUs (granted December 13, 2023), 5,688 PBRSUs (granted February 26, 2024), and 3,324 RSUs (granted November 8, 2024) vested.
• 12,316 shares of common stock were disposed of by the company at a price of $102.14 per share to cover tax withholding obligations related to the vesting events.
• Following these transactions, Chudova directly beneficially owns 17,428 shares of common stock.
• Additionally, Chudova holds derivative securities comprising 4,018 RSUs, 5,002 RSUs, 5,688 PBRSUs, and 23,268 RSUs, totaling 37,976 derivative shares.

Sentiment

Score: 6

Explanation: The filing reports routine equity compensation events, including vesting of RSUs and PBRSUs, and associated tax withholding. The achievement of performance metrics for some awards is positive, while the tax-related share disposition is a standard, neutral event. Overall, it reflects normal course of business for executive compensation.

Positives

• Significant vesting of restricted stock units and performance-based restricted stock units, indicating the achievement of performance metrics for some awards.
• The vesting events represent a realization of equity compensation for the Chief Technology Officer, aligning executive interests with shareholder value.

Negatives

• 12,316 shares were disposed of at $102.14 per share to cover tax withholding obligations, reducing the net shares received by the reporting person.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

This filing reflects routine equity compensation practices common in the biotechnology and healthcare technology sectors, where executive compensation often includes significant equity components like restricted stock units and performance-based awards to align management incentives with shareholder value.

Comparison to Industry Standards

• The use of restricted stock units and performance-based restricted stock units for executive compensation is a standard practice across the technology and healthcare industries, including companies like Illumina, Exact Sciences, and Foundation Medicine.
• The vesting schedules and performance metrics are typical for retaining key talent and incentivizing long-term performance, aligning with common corporate governance benchmarks for executive equity awards.

Related Party Transactions

• The reported transactions involve equity awards granted by Guardant Health, Inc. to its Chief Technology Officer, Darya Chudova, which are considered related party transactions in the context of executive compensation.

Stakeholder Impact

• Shareholders: The vesting and subsequent tax-related sale of shares by a key executive could be seen as a minor increase in the public float, but the overall impact on share price is typically negligible for routine Form 4 filings. The continued equity holdings align executive interests with shareholder value.
• Employees: The vesting of equity awards demonstrates the company's commitment to its compensation plans, which can positively influence employee morale and retention, particularly for those with similar equity incentives.

Next Steps

• The remaining 75% of the November 7, 2022 RSU award vests in equal quarterly installments over the remaining three-year period after October 1, 2023.
• The remaining 67% of the December 13, 2023 RSU award vests in equal quarterly installments over the remaining two-year period after October 1, 2024.
• The remaining 34% of the February 26, 2024 PBRSU award will vest on January 1, 2027.
• The remaining 67% of the November 8, 2024 RSU award vests in equal quarterly installments over the remaining two-year period after October 1, 2025.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, specifically the vesting of restricted stock units and performance-based awards, along with shares withheld for tax purposes. Such filings are generally not considered price-sensitive as they reflect pre-scheduled events rather than discretionary trading or new material information about the company's operational or financial performance. Therefore, it does not provide a basis for a change in investment recommendation, and a 'hold' stance is appropriate based solely on this filing.

Keywords

Guardant Health, GH, Darya Chudova, Chief Technology Officer, SEC Form 4, Insider Transaction, Restricted Stock Units, Performance-Based Restricted Stock Units, Equity Compensation, Stock Vesting, Tax Withholding